Logo image of GOSS

GOSSAMER BIO INC (GOSS) Stock Fundamental Analysis

NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock

0.9022  -0.02 (-2.15%)

Fundamental Rating

1

GOSS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. GOSS has a bad profitability rating. Also its financial health evaluation is rather negative. GOSS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GOSS has reported negative net income.
GOSS had a negative operating cash flow in the past year.
In the past 5 years GOSS always reported negative net income.
GOSS had a negative operating cash flow in each of the past 5 years.
GOSS Yearly Net Income VS EBIT VS OCF VS FCFGOSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

With a decent Return On Assets value of -20.42%, GOSS is doing good in the industry, outperforming 77.52% of the companies in the same industry.
Looking at the Return On Equity, with a value of -132.35%, GOSS is doing worse than 61.77% of the companies in the same industry.
Industry RankSector Rank
ROA -20.42%
ROE -132.35%
ROIC N/A
ROA(3y)-69.97%
ROA(5y)-59.46%
ROE(3y)-791.59%
ROE(5y)-500.36%
ROIC(3y)N/A
ROIC(5y)N/A
GOSS Yearly ROA, ROE, ROICGOSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GOSS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOSS Yearly Profit, Operating, Gross MarginsGOSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for GOSS has been increased compared to 1 year ago.
Compared to 5 years ago, GOSS has more shares outstanding
GOSS has a better debt/assets ratio than last year.
GOSS Yearly Shares OutstandingGOSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
GOSS Yearly Total Debt VS Total AssetsGOSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.80, we must say that GOSS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.80, GOSS is in line with its industry, outperforming 42.65% of the companies in the same industry.
A Debt/Equity ratio of 3.64 is on the high side and indicates that GOSS has dependencies on debt financing.
With a Debt to Equity ratio value of 3.64, GOSS is not doing good in the industry: 84.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.64
Debt/FCF N/A
Altman-Z -3.8
ROIC/WACCN/A
WACCN/A
GOSS Yearly LT Debt VS Equity VS FCFGOSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

GOSS has a Current Ratio of 6.74. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
GOSS has a better Current ratio (6.74) than 65.84% of its industry peers.
GOSS has a Quick Ratio of 6.74. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.74, GOSS is doing good in the industry, outperforming 66.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74
GOSS Yearly Current Assets VS Current LiabilitesGOSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

GOSS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.92%, which is quite impressive.
EPS 1Y (TTM)81.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GOSS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.44% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.27%
EPS Next 2Y21.6%
EPS Next 3Y18.29%
EPS Next 5Y15.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GOSS Yearly Revenue VS EstimatesGOSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GOSS Yearly EPS VS EstimatesGOSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GOSS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOSS Price Earnings VS Forward Price EarningsGOSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOSS Per share dataGOSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

GOSS's earnings are expected to grow with 18.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.6%
EPS Next 3Y18.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOSS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GOSSAMER BIO INC

NASDAQ:GOSS (1/22/2025, 10:43:40 AM)

0.9022

-0.02 (-2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners81.16%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner Change0%
Market Cap204.44M
Analysts82.67
Price Target7.76 (760.12%)
Short Float %2.79%
Short Ratio3.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.66%
Min EPS beat(2)-5.81%
Max EPS beat(2)7.13%
EPS beat(4)3
Avg EPS beat(4)0.95%
Min EPS beat(4)-5.81%
Max EPS beat(4)7.13%
EPS beat(8)7
Avg EPS beat(8)5.49%
EPS beat(12)9
Avg EPS beat(12)3.75%
EPS beat(16)10
Avg EPS beat(16)1.92%
Revenue beat(2)1
Avg Revenue beat(2)1.46%
Min Revenue beat(2)-17.78%
Max Revenue beat(2)20.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.94
P/FCF N/A
P/OCF N/A
P/B 3.78
P/tB 3.78
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.46
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.42%
ROE -132.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.97%
ROA(5y)-59.46%
ROE(3y)-791.59%
ROE(5y)-500.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 3.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z -3.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)37.16%
Cap/Depr(5y)108.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y79.27%
EPS Next 2Y21.6%
EPS Next 3Y18.29%
EPS Next 5Y15.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.61%
EBIT Next 3Y20.68%
EBIT Next 5Y19.44%
FCF growth 1Y99.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.21%
OCF growth 3YN/A
OCF growth 5YN/A